Trademark: 97416720
Word
REINVENTING HOPE
Status
Dead
Status Code
605
Status Date
Monday, May 8, 2023
Serial Number
97416720
Mark Type
4000
Filing Date
Wednesday, May 18, 2022
Published for Opposition
Tuesday, May 2, 2023
Abandoned Date
Monday, May 8, 2023

Trademark Owner History
Teon Therapeutics, Inc. - Owner At Publication

Classifications
5 Pharmaceutical preparations for treating cancer; pharmaceutical preparations for the treatment or prevention of dermatological, cardiovascular, hematological, circulatory, gastroenterological, digestive, hormonal, rheumatic, immune system, and metabolic diseases and disorders; pharmaceutical preparations for use in immunology, oncology including immuno-oncology, cardiovascular and metabolic diseases; pharmaceutical preparations designed to deliver highly targeted therapeutic modulation to patients suffering from a variety of diseases, including cancer, autoimmune and inflammatory diseases including transplantation and delayed-type hypersensitivity, gastrointestinal diseases, cardiovascular and metabolic diseases, and dermatologic diseases, genitourinary diseases, and orphan diseases; protein therapeutics, namely, pharmaceutical preparations for use in immunology including rheumatology, oncology including immuno-oncology, pulmonology, gastroenterology, dermatology, urology, gynecology, hepatology; protein therapeutics, namely, proteins designed to deliver highly targeted therapeutic modulation for patients suffering from a variety of diseases, including cancer and autoimmune disorders, cytokines, interferons, tumor cell targeting and cytolytic agents, tolerogenic and antiallergic factors, growth and differentiation factors, hormones, replacement enzymes, lipid binding proteins, protein factors for manufacturing of adoptive cell therapy products, and tissue repair factors; non-natural protein modifications for use in connection with a variety of therapeutic areas, namely, protein arrays for medical diagnosis purposes; pharmaceutical preparations, namely, synthetic proteins for use in immunology including rheumatology, oncology including immuno-oncology, pulmonology, gastroenterology, dermatology, urology, gynecology, hepatology
42 Medical and pharmaceutical research services; pharmaceutical research and development; research and development in pharmacology for the purpose of treating cancer; medical research for use in oncology; pharmaceutical research for treating neuroendocrine tumors; medical research for the treatment or prevention of dermatological, cardiovascular, hematological, circulatory, gastroenterological, digestive, hormonal, rheumatic, immune system, and metabolic diseases and disorders; providing medical and scientific research information in the field of pharmaceuticals; medical and scientific research, namely, conducting clinical trials for others; laboratory research services relating to pharmaceuticals; pharmaceutical research in the field of protein therapeutics; pharmaceutical research in the fields of immunology including rheumatology, oncology including immuno-oncology, pulmonology, gastroenterology, endocrinology, dermatology, urology, gynecology, hepatology, laboratory medicine, clinical diagnostics, genetics and phenomics, pathology and forensics, proteomics, veterinary medicine and diagnostics, and basic research tools; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; pharmaceutical research using a semi-synthetic organism for use in drug development; pharmaceutical research, namely, research relating to synthetic proteins incorporating one or more non-natural amino acids for improving pharmacological properties; pharmaceutical research, namely, research relating to synthetic proteins for use in connection with a wide variety of therapeutic agents

Trademark Events
May 9, 2023
Abandonment Notice E-Mailed - After Publication
May 8, 2023
Abandonment - After Publication
May 4, 2023
Teas Express Abandonment Received
May 2, 2023
Official Gazette Publication Confirmation E-Mailed
May 2, 2023
Published For Opposition
Apr 12, 2023
Notification Of Notice Of Publication E-Mailed
Mar 29, 2023
Law Office Publication Review Completed
Mar 23, 2023
Assigned To Lie
Mar 8, 2023
Approved For Pub - Principal Register
Mar 8, 2023
Previous Allowance Count Withdrawn
Mar 8, 2023
Approved For Pub - Principal Register
Mar 8, 2023
Examiner's Amendment Entered
Mar 8, 2023
Notification Of Examiners Amendment E-Mailed
Mar 8, 2023
Examiners Amendment E-Mailed
Mar 8, 2023
Examiners Amendment -Written
Mar 7, 2023
Assigned To Examiner
May 24, 2022
New Application Office Supplied Data Entered
May 21, 2022
New Application Entered

Trademark Alertz updated from USPTO on 2030-01-24